Core Insights - Conduit Pharmaceuticals has entered into a collaboration with Charles River Laboratories to evaluate AZD1656 in a Systemic Lupus Erythematosus model, aiming to generate high-quality preclinical data for its clinical program in autoimmune disorders [1][8] - The partnership will leverage Charles River's expertise in immunology to refine study parameters and enhance the predictability of clinical outcomes for the upcoming Phase II trials [2][5] Group 1: Collaboration and Objectives - The collaboration with Charles River is intended to provide essential data that will inform and de-risk future clinical trials, focusing on the drug's impact on disease progression and inflammatory markers [3][4] - The study aims to optimize Phase II trials by reducing development timelines and maximizing the therapeutic potential of AZD1656, which may also enhance the value for potential out-licensing opportunities [4][8] Group 2: Company Overview - Conduit Pharmaceuticals is a clinical-stage life science company that employs an efficient model for compound development, focusing on acquiring and funding Phase 2-ready assets [6] - The company is led by experienced pharmaceutical executives and utilizes a platform-driven approach powered by artificial intelligence and cybernetics, seeking exits through third-party licensing deals following successful clinical trials [6]
Conduit Pharmaceuticals Partners with Charles River in Clinically Relevant Systemic Lupus Erythematosus Model